Novartis headquarters in Basel, Switzerland (Kyle LaHucik for Endpoints News)
Updated: Novartis discontinues lead Gyroscope gene therapy after $800M+ buyout
Novartis is pulling the plug on the lead gene therapy program from a biotech it paid $800 million upfront to acquire, as the Big Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
